Kronos Bio, Inc. (KRON)
- Previous Close
0.9818 - Open
1.0000 - Bid 0.9952 x 200
- Ask 1.0300 x 400
- Day's Range
0.9821 - 1.0343 - 52 Week Range
0.7310 - 2.2900 - Volume
255,282 - Avg. Volume
434,930 - Market Cap (intraday)
61.296M - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9500 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.13
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
www.kronosbio.comRecent News: KRON
Performance Overview: KRON
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRON
Valuation Measures
Market Cap
61.30M
Enterprise Value
-63.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.84
Price/Book (mrq)
0.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.83%
Return on Equity (ttm)
-55.84%
Revenue (ttm)
6.29M
Net Income Avi to Common (ttm)
-112.67M
Diluted EPS (ttm)
-1.9500
Balance Sheet and Cash Flow
Total Cash (mrq)
173M
Total Debt/Equity (mrq)
17.77%
Levered Free Cash Flow (ttm)
-43.83M
Research Analysis: KRON
Company Insights: KRON
KRON does not have Company Insights